Skip to main content
SpringerLink
Log in

Peg-IFN α-2a best first-line strategy in hepatitis B

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Bermingham SL, et al. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom. Value in Health 18: 800-9, No. 6, Sep 2015. Available from: URL: http://doi.org/10.1016/j.jval.2015.05.007

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peg-IFN α-2a best first-line strategy in hepatitis B. PharmacoEcon Outcomes News 738, 24 (2015). https://doi.org/10.1007/s40274-015-2506-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2506-y

Search

Navigation